Supplemental Table 1. Significant Adverse Events

Event	CTCAE Grade	Attribution to rituximab
Lower GI hemorrhage	2	Unlikely
Heart failure	3	Not related
Line associated bacteremia	3	Possible
Chest pain	3	Unlikely
Atrial fibrillation	3	Unlikely
Hypotension	3	Unlikely
Cellulitis	3	Unlikely
Respiratory failure	4	Probable

Supplemental Table 2. Reason for exclusion of potential patients

Exclusion basis	Number of excluded patients
ADAMTS 13 activity > 10%	12
Patient declined participation	7
Current participation in other trials	5
Exceeded allowable number of plasma exchange prior to enrollment	4
Diagnosis of cancer	3
Pregnancy	3
Unable to provide consent	3
Lack of insurance	3
Unable to complete followup at study hospital	3
Age < 18	2
Rituximab within previous year	2
Severe hypertension (SBP >180, DBP>120)	1
Congenital TTP	1
HIV positive	1
History of Hepatitis B	1
Limited life expectancy	1

Additional ART Investigators:

Erik Uhlmann

Kenneth A Bauer

Vanetta Worthy

Thomas Bogue